Description: Monopar Therapeutics is a clinical stage biopharmaceutical company focused on developing proprietary therapeutics designed to improve clinical outcomes for cancer patients. The company's pipeline consists of Validive® for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for advanced soft tissue sarcoma; and a late-stage preclinical antibody MNPR-101.
Home Page: www.monopartx.com
MNPR Technical Analysis
1000 Skokie Boulevard
Wilmette,
IL
60091
United States
Phone:
847 388 0349
Officers
| Name | Title |
|---|---|
| Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc | Co-Founder, CEO, Pres & Director |
| Ms. Kim R. Tsuchimoto CPA | CFO, Sec. & Treasurer |
| Mr. Andrew J. Cittadine M.B.A. | Chief Operating Officer |
| Dr. Patrice P. Rioux M.D., Ph.D. | Acting Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.7233 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2019-12-19 |
| Fiscal Year End: | December |
| Full Time Employees: | 9 |